A multicenter prospective study comprising identical methods of P. jirovecii screening in CF patients including those who have undergone lung-transplantation, with patient-age stratification, CFTR mutation analysis, and MLST/NGS analysis of the P. jirovecii genome combined with microbiome/mycobiome examination is warranted. This evidence concerns the gene CFTR and cystic fibrosis.